SLC5A2 and type 2 diabetes mellitus: A recent meta-analysis of 39 RCTs, involving >60,000 patients with T2D, confirmed SGLT2 inhibitors were statistically associated with an increased risk of DKA versus control (OR 2.13, 95% CI 1.38, 3.27) [91].